These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 23342479)

  • 1. [New insights in the pathogenesis and treatment of rosacea].
    Palatsi R; Kelhälä HL; Hägg P
    Duodecim; 2012; 128(22):2327-35. PubMed ID: 23342479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Antimicrobial peptides, Vitamin D₃ and more. How rosacea may develop].
    Schauber J
    Hautarzt; 2011 Nov; 62(11):815-9. PubMed ID: 22002717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cathelicidin peptide LL-37 increases UVB-triggered inflammasome activation: possible implications for rosacea.
    Salzer S; Kresse S; Hirai Y; Koglin S; Reinholz M; Ruzicka T; Schauber J
    J Dermatol Sci; 2014 Dec; 76(3):173-9. PubMed ID: 25306296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Novel Mechanism of Carvedilol Efficacy for Rosacea Treatment: Toll-Like Receptor 2 Inhibition in Macrophages.
    Zhang J; Jiang P; Sheng L; Liu Y; Liu Y; Li M; Tao M; Hu L; Wang X; Yang Y; Xu Y; Liu W
    Front Immunol; 2021; 12():609615. PubMed ID: 34322115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Light-emitting diodes downregulate cathelicidin, kallikrein and toll-like receptor 2 expressions in keratinocytes and rosacea-like mouse skin.
    Lee JB; Bae SH; Moon KR; Na EY; Yun SJ; Lee SC
    Exp Dermatol; 2016 Dec; 25(12):956-961. PubMed ID: 27315464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Rosacea 2009 : new advances in pathophysiology, clinical staging and therapeutic strategies].
    Sobottka A; Lehmann P
    Hautarzt; 2009 Dec; 60(12):999-1009. PubMed ID: 19957073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TLR2 expression is increased in rosacea and stimulates enhanced serine protease production by keratinocytes.
    Yamasaki K; Kanada K; Macleod DT; Borkowski AW; Morizane S; Nakatsuji T; Cogen AL; Gallo RL
    J Invest Dermatol; 2011 Mar; 131(3):688-97. PubMed ID: 21107351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic isotretinoin in the treatment of rosacea - doxycycline- and placebo-controlled, randomized clinical study.
    Gollnick H; Blume-Peytavi U; Szabó EL; Meyer KG; Hauptmann P; Popp G; Sebastian M; Zwingers T; Willers C; von der Weth R
    J Dtsch Dermatol Ges; 2010 Jul; 8(7):505-15. PubMed ID: 20337772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cathelicidin, kallikrein 5, and serine protease activity is inhibited during treatment of rosacea with azelaic acid 15% gel.
    Coda AB; Hata T; Miller J; Audish D; Kotol P; Two A; Shafiq F; Yamasaki K; Harper JC; Del Rosso JQ; Gallo RL
    J Am Acad Dermatol; 2013 Oct; 69(4):570-7. PubMed ID: 23871720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Facial Dermatitis and Rosacea.
    Fowler JF
    Semin Cutan Med Surg; 2016 Jun; 35(6 Suppl):S107-9. PubMed ID: 27537212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ocular surface changes in the treatment of rosacea: comparison between low-dose oral isotretinoin and doxycycline.
    Andrade FMX; Picosse FR; Cunha LPD; Valente CM; Bezerra FM; Miot H; Bagatin E; Freitas D
    Arq Bras Oftalmol; 2020; 83(2):109-112. PubMed ID: 31778446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Sunscreen, antibiotics, laser. What can you do against rosacea?].
    Gross H
    MMW Fortschr Med; 2009 Dec; 151(51-52):18-9. PubMed ID: 20088315
    [No Abstract]   [Full Text] [Related]  

  • 13.
    Roh KB; Ryu DH; Cho E; Weon JB; Park D; Kweon DH; Jung E
    Molecules; 2020 Nov; 25(23):. PubMed ID: 33256158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased expression of cathelicidin by direct activation of protease-activated receptor 2: possible implications on the pathogenesis of rosacea.
    Kim JY; Kim YJ; Lim BJ; Sohn HJ; Shin D; Oh SH
    Yonsei Med J; 2014 Nov; 55(6):1648-55. PubMed ID: 25323904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endoplasmic reticulum stress: key promoter of rosacea pathogenesis.
    Melnik BC
    Exp Dermatol; 2014 Dec; 23(12):868-73. PubMed ID: 25047092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea.
    Yamasaki K; Di Nardo A; Bardan A; Murakami M; Ohtake T; Coda A; Dorschner RA; Bonnart C; Descargues P; Hovnanian A; Morhenn VB; Gallo RL
    Nat Med; 2007 Aug; 13(8):975-80. PubMed ID: 17676051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel sulfated polysaccharides disrupt cathelicidins, inhibit RAGE and reduce cutaneous inflammation in a mouse model of rosacea.
    Zhang J; Xu X; Rao NV; Argyle B; McCoard L; Rusho WJ; Kennedy TP; Prestwich GD; Krueger G
    PLoS One; 2011 Feb; 6(2):e16658. PubMed ID: 21347371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Colchicine Alleviates Rosacea by Inhibiting Neutrophil Inflammation Activated by the TLR2 Pathway.
    Yuan X; Sheng L; Shi G; Jiang L; Lian C
    Inflammation; 2024 Jun; 47(3):1002-1014. PubMed ID: 38279067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Rosacea: New data for better care].
    Cribier B
    Ann Dermatol Venereol; 2017; 144(8-9):508-517. PubMed ID: 28728857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rosacea fulminans with extrafacial lesions in an elderly man: successful treatment with subantimicrobial-dose doxycycline.
    Smith LA; Meehan SA; Cohen DE
    J Drugs Dermatol; 2014 Jun; 13(6):763-5. PubMed ID: 24918570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.